156 related articles for article (PubMed ID: 31745730)
1. The prognostic value of NRF2 in breast cancer patients: a systematic review with meta-analysis.
Almeida M; Soares M; Ramalhinho AC; Moutinho JF; Breitenfeld L; Pereira L
Breast Cancer Res Treat; 2020 Feb; 179(3):523-532. PubMed ID: 31745730
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of NRF2 is correlated with prognoses of patients with malignancies: A meta-analysis.
Guo Y; Shen L
Thorac Cancer; 2017 Nov; 8(6):558-564. PubMed ID: 28766861
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Significance of FOXC1 in Various Cancers: A Systematic Review and Meta-Analysis.
Sabapathi N; Sabarimurugan S; Madurantakam Royam M; Kumarasamy C; Xu X; Xu G; Jayaraj R
Mol Diagn Ther; 2019 Dec; 23(6):695-706. PubMed ID: 31372939
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of MMP Family Members Functions as Prognostic Biomarker for Breast Cancer Patients: A Systematic Review and Meta-Analysis.
Ren F; Tang R; Zhang X; Madushi WM; Luo D; Dang Y; Li Z; Wei K; Chen G
PLoS One; 2015; 10(8):e0135544. PubMed ID: 26270045
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and clinicopathological significance of NRF2 expression in non-small cell lung cancer: A meta-analysis.
Wang Q; Xu L; Wang G; Chen L; Li C; Jiang X; Gao H; Yang B; Tian W
PLoS One; 2020; 15(11):e0241241. PubMed ID: 33186371
[TBL] [Abstract][Full Text] [Related]
6. High NF-E2-related factor 2 expression predicts poor prognosis in patients with lung cancer: a meta-analysis of cohort studies.
Yang Q; Deng H; Xia H; Xu M; Pan G; Mao J; Tao S; Yamanaka K; An Y
Free Radic Res; 2020 Dec; 54(11-12):790-798. PubMed ID: 31298052
[TBL] [Abstract][Full Text] [Related]
7. NRF2 promotes breast cancer cell proliferation and metastasis by increasing RhoA/ROCK pathway signal transduction.
Zhang C; Wang HJ; Bao QC; Wang L; Guo TK; Chen WL; Xu LL; Zhou HS; Bian JL; Yang YR; Sun HP; Xu XL; You QD
Oncotarget; 2016 Nov; 7(45):73593-73606. PubMed ID: 27713154
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients.
Petrelli F; Viale G; Cabiddu M; Barni S
Breast Cancer Res Treat; 2015 Oct; 153(3):477-91. PubMed ID: 26341751
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis.
Gonzalez-Conchas GA; Rodriguez-Romo L; Hernandez-Barajas D; Gonzalez-Guerrero JF; Rodriguez-Fernandez IA; Verdines-Perez A; Templeton AJ; Ocana A; Seruga B; Tannock IF; Amir E; Vera-Badillo FE
Cancer Treat Rev; 2018 Jan; 62():1-8. PubMed ID: 29126017
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data.
Matikas A; Zerdes I; Lövrot J; Richard F; Sotiriou C; Bergh J; Valachis A; Foukakis T
Clin Cancer Res; 2019 Sep; 25(18):5717-5726. PubMed ID: 31227501
[TBL] [Abstract][Full Text] [Related]
11. Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis.
Li L; Han D; Wang X; Wang Q; Tian J; Yao J; Yuan L; Qian K; Zou Q; Yi W; Zhou E; Yang K
Future Oncol; 2017 May; 13(11):1021-1034. PubMed ID: 28088868
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of matrix metalloproteinase 9 expression in breast cancer patients: a meta-analysis.
Song J; Su H; Zhou YY; Guo LL
Asian Pac J Cancer Prev; 2013; 14(3):1615-21. PubMed ID: 23679245
[TBL] [Abstract][Full Text] [Related]
13. Prognosis difference between HER2-low and HER2-zero breast cancer patients: a systematic review and meta-analysis.
Li C; Yuan Q; Deng T; Xu G; Hou J; Zheng L; Wu G
Breast Cancer; 2023 Nov; 30(6):965-975. PubMed ID: 37470943
[TBL] [Abstract][Full Text] [Related]
14. Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis.
Li S; Shen Y; Wang M; Yang J; Lv M; Li P; Chen Z; Yang J
Oncotarget; 2017 May; 8(19):32043-32054. PubMed ID: 28410191
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and clinicopathological significance of cyclin B expression in patients with breast cancer: A meta-analysis.
Sun X; Zhangyuan G; Shi L; Wang Y; Sun B; Ding Q
Medicine (Baltimore); 2017 May; 96(19):e6860. PubMed ID: 28489780
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and clinical significance of syndecan-1 expression in breast cancer: A systematic review and meta-analysis.
Qiao W; Liu H; Guo W; Li P; Deng M
Eur J Surg Oncol; 2019 Jul; 45(7):1132-1137. PubMed ID: 30598194
[TBL] [Abstract][Full Text] [Related]
17. Nrf2 overexpression predicts prognosis and 5-FU resistance in gastric cancer.
Hu XF; Yao J; Gao SG; Wang XS; Peng XQ; Yang YT; Feng XS
Asian Pac J Cancer Prev; 2013; 14(9):5231-5. PubMed ID: 24175806
[TBL] [Abstract][Full Text] [Related]
18. Metformin diminishes the unfavourable impact of Nrf2 in breast cancer patients with type 2 diabetes.
Urpilainen E; Kangaskokko J; Puistola U; Karihtala P
Tumour Biol; 2019 Jan; 41(1):1010428318815413. PubMed ID: 30803422
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms and protein expression of NRF2 and Sulfiredoxin predict survival outcomes in breast cancer.
Hartikainen JM; Tengström M; Kosma VM; Kinnula VL; Mannermaa A; Soini Y
Cancer Res; 2012 Nov; 72(21):5537-46. PubMed ID: 22964583
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and clinicopathological value of Twist expression in breast cancer: A meta-analysis.
Qiao W; Jia Z; Liu H; Liu Q; Zhang T; Guo W; Li P; Deng M; Li S
PLoS One; 2017; 12(10):e0186191. PubMed ID: 29016671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
